Wave Life Sciences, Inc. (WVE) News
Follow Wave Life Sciences, Inc. (WVE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Wave Life Sciences, Inc. (WVE) Gets $12M As GSK Selects Hepatology siRNA
Wave Life Sciences will receive a $12M milestone after GSK selected a hepatology GalNAc-siRNA candidate from their collaboration; three additional programs are advancing toward candidate selection.Material DetailsContext
NEWS | Sep 30, 2026, 11:38 AM UTC
L
Wave Life Sciences Announces Gsk’S Selection Of Sirna Program To Transition To Gsk For Further Development
Wave Life Sciences Ltd. NASDAQ:WVE
NEWS | Sep 30, 2026, 11:32 AM UTC
L
Weekly Recap: INLIGHT Phase 2a for WVE-007 and Dr. Vnuk 375k-share option
Wave Life Sciences Inc (NASDAQ:WVE) launched a Phase 2a INLIGHT trial testing WVE-007 alone and with tirzepatide for weight- and muscle-loss in adults with obesity, while granting Dr. Vnuk an option for 375,000 WVE share
EQUITY | Sep 28, 2026, 11:03 AM UTC
L
Wave Life Sciences Cut to Neutral From Overweight by JP Morgan
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 12:28 PM UTC
L
Wave Life Sciences Initiates Phase 2A Combination Trial Of WVE-007 (GalNAc-siRNA) With Tirzepatide For Obesity
Wave Life Sciences Ltd. NASDAQ:WVE
NEWS | Sep 23, 2026, 12:05 PM UTC
L
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave’s INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 a
NEWS | Sep 23, 2026, 11:32 AM UTC
L
WVE - Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
WVE - Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
NEWS | Sep 23, 2026, 11:30 AM UTC
L
WVE - Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
WVE - Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
NEWS | Sep 22, 2026, 11:30 AM UTC
L
WVE: Durable RNA editing and innovative obesity trials drive clinical and regulatory progress in 2024
RNA editing has advanced with highly specific, durable correction in clinical programs like AATD and PNPLA3, supported by chemistry innovations and new trial designs. The Inhibin E program is progressing in obesity and c
EQUITY | Sep 10, 2026, 03:07 PM UTC
L
WVE: Durable RNA editing and Inhibin E programs advance, with pivotal data and regulatory updates expected
RNA editing programs have shown high specificity and durable correction in clinical studies, with AATD and PNPLA3 advancing toward pivotal trials and regulatory discussions. The Inhibin E program is progressing in obesit
EQUITY | Sep 10, 2026, 02:37 PM UTC
L
Wave Life Sciences CEO Bolno to present at Cantor 2026 conference
Wave Life Sciences Ltd. said Paul Bolno, MD, MBA, President and CEO, will present at the Cantor 2026 Global Healthcare Conference.
EQUITY | Sep 03, 2026, 08:07 PM UTC
L
Wave Life Sciences to present at Cantor 2026 healthcare conference
Wave Life Sciences plans to present at the Cantor 2026 Global Healthcare Conference.
EQUITY | Sep 03, 2026, 08:06 PM UTC
L
Wave Life Sciences Redomiciling To Delaware
Wave Life Sciences announces redomiciliation completion date
EQUITY | Aug 05, 2026, 08:06 PM UTC
L
WVE - Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
WVE - Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Jul 30, 2026, 11:30 AM UTC
M
WVE Initiates Phase 2a Trial
Wave Life Sciences initiates Phase 2a portion of INLIGHT trial of WVE-007 for obesity and cardiometabolic diseases
EQUITY | Jun 24, 2026, 12:31 PM UTC